What is Biofrontera?
Founded in 1997, Biofrontera operates at the intersection of advanced dermatology and medical aesthetics. The company specializes in the research, development, and commercial distribution of innovative drugs and therapeutic cosmetics designed for skin protection and treatment. Headquartered in Germany, Biofrontera has established itself as a key player in the dermatological market, focusing on high-efficacy treatments that address complex skin conditions. Its business model integrates rigorous clinical development with a strategic commercialization strategy, allowing the firm to maintain a competitive edge in the highly regulated pharmaceutical industry. By prioritizing patient outcomes and dermatological health, Biofrontera continues to refine its product offerings to meet the evolving needs of both medical professionals and consumers worldwide.
How much funding has Biofrontera raised?
Biofrontera has raised a total of $47.9M across 2 funding rounds:
Share Placement
$29.9M
Stock Offering
$18M
Share Placement (2021): $29.9M, investors not publicly disclosed
Stock Issuance/Offering (2021): $18M, investors not publicly disclosed
Key Investors in Biofrontera
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Biofrontera?
Looking ahead, Biofrontera is poised to utilize its recent capital infusion to drive long-term growth and operational excellence. The strategic focus will likely center on scaling its commercial infrastructure and deepening its investment in clinical research to support the next generation of dermatological therapies. As the company navigates the complexities of the global healthcare market, this financial backing provides the necessary runway to pursue international expansion and enhance its market penetration. Investors and industry analysts will be monitoring the firm's ability to translate this capital into sustained revenue growth and continued innovation in the specialized field of skin health, marking a pivotal chapter in the company's corporate evolution.
See full Biofrontera company page
